Ivonescimab for the Treatment of Thymic Cancer

NCT06980077 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
25
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators